AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 91 min read$OPCH

UBS Downgrades Option Care Health to Neutral From Buy, Price Target is $32.05

UBS downgraded Option Care Health to 'Neutral' from 'Buy' and set a price target of $32.05. The stock has a 5-day change of +0.13% and a 1st Jan change of +37.51%. The downgrade is based on valuation, EPS revisions, and visibility metrics.

Original reporting
marketscreener.com
Published Oct 9, 2026, 11:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$OPCH
Bearish
high confidence
Mentioned
$OPCH
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$OPCHBearishMed
01

Why it matters

The downgrade could prompt short‑term selling pressure, especially in pre‑market trading, and may influence peer valuation in the specialty pharmacy sector.

02

Market read

Analyst rating changes are a common catalyst for short‑term price moves; this downgrade is the primary news driver for OPCH today.

03

What to watch

Potential upcoming contract renewals or cost‑reduction initiatives not covered in the downgrade.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Option Care Health (OPCH) is a specialty pharmacy provider. UBS analysts revised their outlook, moving the rating from Buy to Neutral and lowering the price target.

Company-level read

Ticker impact

$OPCHBearishHigh confidence
Context

UBS downgraded Option Care Health to Neutral and set a new $32.05 price target.

Expected impact

likely downward pressure as investors price in the lower rating

Evidence & confidence

Analyst downgrades are a direct catalyst that often lead to short-term price declines.

Market effects

Sector

May weigh on other specialty health‑care stocks as analysts reassess sector outlook.

Regional

Limited to U.S. markets; no broader regional effect.

Global

Minimal global impact beyond U.S. specialty health‑care niche.

Counterpoint

What could challenge this read

Some investors may view the downgrade as an overreaction if the company’s fundamentals remain solid.

Key entities

  • company
    Option Care Health

    U.S.-listed specialty pharmacy firm (ticker OPCH).

  • analyst_firm
    UBS

    Investment bank providing the downgrade and new price target.

Read at source← All news

Related articles

OCT 10
$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

tradingview.com1 min
OCT 10
$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

hoodline.com2 min
OCT 9
$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

finance.yahoo.com2 min
OCT 7
$OPCHHighAI 9/10

Infusion therapy provider being acquired in $5.8 billion deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, expected to close in early 2027. CD&R will hold majority ownership, with McKesson holding a minority stake. Option Care Health shares were trading at $31.02, up from $23.34 before the acquisition news. The company will remain separate but will delist from Nasdaq post-deal.

wfmz.com2 min
OCT 7
$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

finance.yahoo.com2 min